Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DIM-C-pPhCl** is a synthetic small molecule belonging to the class of bis-indole-derived compounds known as C-DIMs. Its chemical name is 1,1-bis(3'-indolyl)-1-(p-chlorophenyl)methane. DIM-C-pPhCl acts as a **selective agonist of the orphan nuclear receptor Nurr1 (NR4A2)**, with limited activity on closely related receptors such as Nur77 and Nor1. In cell and animal models, it induces expression of pro-apoptotic and anti-proliferative genes and demonstrates significant antitumor activity, most notably through **activation of Nurr1-dependent transcription** and apoptosis in cancer cells. It has been studied preclinically for antineoplastic properties, including tumor growth inhibition and induction of apoptosis in models of bladder, colon, pancreatic, and other cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dim-c-pphcl.